These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30844945)

  • 1. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
    Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic therapy for Behçet's uveitis: a systematic review.
    Uke P; Gorodkin R; Beare N
    Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
    Thomas AS; Lin P
    Curr Opin Ophthalmol; 2020 May; 31(3):174-184. PubMed ID: 32168001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements in the management of uveitis.
    Schwartzman S
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
    Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
    Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics in the Treatment of Uveitis.
    Dingerkus VLS; Becker MD; Doycheva D
    Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of biological treatment for uveitis.
    Gaggiano C; Sota J; Gentileschi S; Caggiano V; Grosso S; Tosi GM; Frediani B; Cantarini L; Fabiani C
    Expert Rev Clin Immunol; 2020 Aug; 16(8):787-811. PubMed ID: 32700605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotherapies in Uveitis.
    Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
    Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
    Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
    Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
    Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
    Liu W; Bai D; Kou L
    BMC Ophthalmol; 2023 May; 23(1):240. PubMed ID: 37248486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in the treatment of uveitis.
    Imrie FR; Dick AD
    Curr Opin Ophthalmol; 2007 Nov; 18(6):481-6. PubMed ID: 18163000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert opinion on the use of biological therapy in non-infectious uveitis.
    Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.